Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer
Open Access
Abstract
BACKGROUND: To the authors' knowledge, the benefit of primary tumor resection among patients with metastatic inflammatory breast cancer (IBC) is unknown.METHODS: The authors reviewed 172 cases of metastatic IBC. All patients received chemotherapy with or without radiotherapy and/or surgery. Patients were classified as responders or nonresponders to chemotherapy. The 5‐year overall survival (OS) and distant progression‐free survival (DPFS) and local control at the time of last follow‐up were evaluated.RESULTS: A total of 79 patients (46%) underwent surgery. OS and DPFS were better among patients treated with surgery versus no surgery (47% vs 10%, respectively [P < .0001] and 30% vs 3%, respectively [P < .0001]). Surgery plus radiotherapy was associated with better survival compared with treatment with surgery or radiotherapy alone (OS rate: 50% vs 25% vs 14%, respectively; DPFS rate: 32% vs 18% vs 15%, respectively [P < .0001 for both]). Surgery was associated with better survival for both responders (OS rate for surgery vs no surgery: 49% vs 23% [P < .0001] and DPFS rate for surgery vs no surgery: 31% vs 8% [P < .0001]) and nonresponders (OS rate for surgery vs no surgery: 40% vs 6% [P < .0001] and DPFS rate for surgery vs no surgery: 30% vs 0% [P < .0001]). On multivariate analysis, treatment with surgery plus radiotherapy and response to chemotherapy were found to be significant predictors of better OS and DPFS. Local control at the time of last follow‐up was 4‐fold more likely in patients who underwent surgery with or without radiotherapy compared with patients who received chemotherapy alone (81% vs 18%; P < .0001). Surgery and response to chemotherapy independently predicted local control on multivariate analysis.CONCLUSIONS: The results of the current study demonstrate that for select patients with metastatic IBC, multimodality treatment including primary tumor resection may result in better local control and survival. However, a randomized trial is needed to validate these findings. Cancer 2014;120:1319–1328. © 2014 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentAnnals of Oncology, 2010
- Inflammatory breast cancer—The Royal Marsden Hospital experienceCancer, 2010
- Management of Inflammatory Breast Cancer After Neoadjuvant ChemotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Incidence of and survival following brain metastases among women with inflammatory breast cancerAnnals of Oncology, 2010
- Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosisEuropean Journal of Surgical Oncology, 2009
- Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survivalBreast Cancer Research and Treatment, 2008
- Complete Excision of Primary Breast Tumor Improves Survival of Patients With Metastatic Breast Cancer at DiagnosisJournal of Clinical Oncology, 2006
- Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic diseaseCancer, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000